KQ3 – How can antibody efficacy be increased using combinations?

KQ3 – How can antibody efficacy be increased using combinations?
(Nathalie Bonnefoy, Thierry Chardès, Gilles Paintaud)

Our objectives in this area are to investigate how therapeutic antibodies can be used in combination to treat disease, either by the association of antibodies targeting different antigens, cells or processes, or by combining antibodies with other forms of therapy. Our lines of research include:

  • Combining antibodies to combat cancer: targeting the tumour cells, targeting the tumour microenvironment and controlling immune checkpoints
  • Associating monoclonal antibodies with other therapies
  • Performing PK/PD studies on antibody combinations